Relapsed or Refractory Hematologic Malignancies Clinical Trials in Beijing, Beijing Municipality
2 recruitingBeijing, Beijing Municipality, China
Showing 1–2 of 2 trials
Recruiting
Phase 1
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Relapsed or Refractory Hematologic Malignancies
Qilu Pharmaceutical Co., Ltd.186 enrolled1 locationNCT07173595
Recruiting
Phase 1
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
Relapsed or Refractory Hematologic Malignancies
Sinocelltech Ltd.74 enrolled1 locationNCT06252298